Diabetes Mellitus, Type 2
Conditions
Brief summary
To evaluate the pharmacokinetic characteristics of pyroglutamate rongliflozin capsules in subjects with mild and moderate liver damage and healthy subjects
Interventions
Subjects will receive one 50mg capsule on Day 1
Sponsors
Sunshine Lake Pharma Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Sign the informed consent form before the experiment, understand and abide by the research process, and participate voluntarily; * Adult subjects between the ages of 18 and 70 (including boundary values), both male and female; * Female subjects or male subjects with potential fertility must agree to use effective contraceptive methods (see Appendix 2 for specific contraceptive methods) from signing informed consent to taking the trial drug within 4 weeks to avoid pregnancy or make their partners pregnant. * The following selection criteria are only applicable to healthy subjects with normal liver function (groups A and C): the gender and age (+ or - 5 years) of subjects in groups A and C are matched with subjects in groups B and D respectively; * The following selection criteria are only applicable to healthy subjects with normal liver function (groups A and C): body mass index (BMI): 18-30kg/m2 (including cut-off value) \[BMI=weight (kg)/height 2 (m2) )\] (BMI matching between groups A and C and groups B and D is + or - 15%); * The following selection criteria are only applicable to healthy subjects with normal liver function (groups A and C): medical history, physical examination, vital signs monitoring, electrocardiogram, laboratory tests (blood routine, urine routine, blood biochemistry, coagulation) Function), alpha-fetoprotein (AFP), abdominal B-ultrasound (liver, spleen, gallbladder, pancreas, kidneys), and chest radiographs have normal or abnormal results, but the investigator judges them to be of no clinical significance. * The following selection criteria are only applicable to subjects with liver dysfunction (groups B and D): for subjects with liver dysfunction without ascites, subclinical ascites, clinically mild and moderate ascites detected only by ultrasound or other imaging , Allow the body mass index (BMI) to be between 18-30 kg/m2 (including the critical value) \[BMI= weight (kg) / height 2 (m2)\]; * The following selection criteria are only applicable to subjects with liver dysfunction (groups B and D): according to the Child-Pugh classification (see Appendix 3) at the time of screening to evaluate the severity of patients with liver dysfunction in accordance with: (Grade A/Mild: Child -Pugh score 5 or 6 points; B grade/moderate: Child Pugh score 7-9 points); * The following selection criteria are only applicable to subjects with liver dysfunction (groups B and D): combined with previous medical history, physical examination results, serological indicators (such as albumin, ALT, AST, bilirubin, prothrombin time, INR, etc.) ) And one of the following tests performed with standard diagnostic and treatment methods that meets the diagnostic basis for chronic liver disease: liver biopsy, computed tomography, magnetic resonance imaging, ultrasound, radioactive liver/spleen scan, laparoscopy; * The following selection criteria are only applicable to subjects with liver damage (groups B and D): within 1 month before taking the test drug or 5 half-lives of the concomitant drug (whichever is longer) to the end of the study Those who have stable medication regimens for the treatment of liver dysfunction, liver disease complications and other concomitant diseases without adjustment (including the type of medication, dosage, or frequency of medication) or those who have not taken medication before enrollment; however, the study doctor's judgment does not affect Except for the adjustment of subject safety and pharmacokinetic endpoints; * The following selection criteria are only applicable to subjects with liver dysfunction (groups B and D): the investigator judges that the liver function status of the subjects is stable and will not deteriorate significantly during the period from 1 month before taking the test drug to the end of the study By.
Exclusion criteria
* The subject has a history of severe allergies or allergies to the test drug and any of its components or related excipients; * People with history of gastrointestinal or kidney disease or surgery (except for uncomplicated appendicitis resection and hernia repair) that may potentially affect the absorption, distribution, metabolism, and excretion of the test drug in the 6 months prior to screening, or the presence can make compliance People with reduced disease; * The researcher judged that he currently has bleeding disorders, such as gastric and duodenal ulcers; * People with a history of liver cancer or other malignant tumors before signing the informed consent form \[exceptions: specific cancers (basal cell carcinoma of the skin, squamous cell carcinoma, or cervical carcinoma in situ, etc.) that are surgically removed and completely cured can be selected\] or are currently assessed for existence People with potential malignant tumors; * Patients with a history of repeated urinary tract infections or/and genital infections within 6 months before screening (recurrent urinary tract infection is defined as: repeated urinary tract infections \> or = 2 times within 6 months, or repeated urinary tract infections in the past 12 months Infection \> or =3 times); * People with a history of recurring severe unconscious hypoglycemia (repeated severe hypoglycemia is defined as: 2 severe neurological symptoms in 4 weeks, hypoglycemia requiring the assistance of others to treat, or 2 blood glucose in 4 weeks\< 3.0 mmol/L, or blood glucose \< or = 3.9 mmol/L \> or =3 times detected within 1 week); * People with a history of alcoholism (alcoholism is defined as: drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine) or those who have a positive alcohol breath test during the screening period; * Those who have a history of drug abuse or have used drugs within 2 years before screening or those who have a positive urine drug screening during the screening period; * Those who smoked more than 5 cigarettes a day in the 3 months before screening or who could not give up smoking from signing informed consent to leaving the group; * Treponema pallidum antibody and/or human immunodeficiency virus (HIV) antibody test results are positive; * Have taken food or drinks that affect CYP3A4 metabolic enzymes, such as grapefruit or drinks containing grapefruit within 7 days before the first medication; * Consume chocolate, any food or drink that contains caffeine or is rich in xanthine within 72 hours before the first medication; * Have taken any alcohol-containing products within 48 hours before the first medication; * Those who donated blood \> or = 400 mL or a large amount of blood loss within 3 months before screening, or who have a history of blood transfusion within 1 month before screening, or who plan to donate blood within 1 month after the end of the test; * Have taken similar SGLT-2 inhibitor drugs within 14 days before screening or participated in other clinical trials within 3 months before screening (if the subject withdrew from the study before treatment, that is, not randomized or received treatment, they can be included in the group Research); * The subject is breastfeeding or the result of serum pregnancy is positive; * Take the prohibited concomitant medications within 1 month before taking the trial drug or within the 5 half-life period of the concomitant medication (whichever is the longer) to the end of the study (see Chapter 5.5.1 for details); * The investigator believes that there are other subjects who are not suitable for participating in this trial (such as inability to tolerate oral drugs, poor peripheral venous access conditions, or significant risks to the subjects, etc.). * The following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | 0 hour（pre-dose） to 96 hours after administration | Maximum plasma concentration of study drugs |
| AUC | 0 hour（pre-dose） to 96 hours after administration | Maximum plasma concentration of study drugs |
| Adverse Events | Day -1 (Baseline) to Day 5 | Incidence of adverse events |
Countries
China
Outcome results
None listed